FindTrial
Sign In

ITM11 Expanded Access Program

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT07497984
Enrollment
Unknown
Registered
2026-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningioma

Brief summary

This Expanded Access Program (EAP) is intended to provide eligible participants with access to ITM-11 prior to approval by local regulatory authorities. Program availability is subject to country eligibility. The treating physician must determine, based on the individual patient´s medical history and the program eligibility criteria, whether the potential benefits outweigh the risks of treatment with an investigational therapy.

Interventions

DRUGITM-11

Intravenous (IV) infusion

Sponsors

ITM Solucin GmbH
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

\-

Exclusion criteria

\-

Contacts

CONTACTMedical Affairs
medical.affairs@itm-radiopharma.com609-785-5839

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026